Skip to main content

RA Capital Healthcare Fund LP's Form 4 filing

Bambusa Therapeutics, Inc.BBTX · filed Nov 3, 2026

Accession no.
0001231919-26-001533
Filed
Nov 3, 2026, 6:09 PM ET
Trade date
Oct 30-Nov 2, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market purchases total $46.6M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
RA Capital Healthcare Fund LPCIK 0001315082Director, 10% Owner
Ra Capital Management, L.P.CIK 0001346824Director, 10% Owner
Kolchinsky PeterCIK 0001384859Director, 10% Owner
Shah Rajeev M.CIK 0001619841Director, 10% Owner
RA Capital Nexus Fund III, L.P.CIK 0001883840Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 30, 2026Common StockPPurchaseAcquired+189,909$14.23F1+$2,702,405.07189,909Indirect
Oct 30, 2026Common StockPPurchaseAcquired+263,911$14.92F4+$3,937,552.12453,820Indirect
Nov 2, 2026Common StockCConversionAcquired+3,144,858–F5–3,598,678Indirect
Nov 2, 2026Common StockCConversionAcquired+1,331,080–F5–1,331,080Indirect
Nov 2, 2026Common StockPPurchaseAcquired+2,335,109$16.00+$37,361,7445,933,787Indirect
Nov 2, 2026Common StockPPurchaseAcquired+164,891$16.00+$2,638,2561,495,971Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 2, 2026Common StockCConversionDisposed−2,844,910$0.00$00Indirect
Nov 2, 2026Common StockCConversionDisposed−1,278,148$0.00$00Indirect
Nov 2, 2026Common StockCConversionDisposed−299,948$0.00$00Indirect
Nov 2, 2026Common StockCConversionDisposed−52,932$0.00$00Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.61 to $14.58 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $15.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.

Referenced by the price of 2 transactions in Table I.

Remarks

Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.

Read the full filing on SEC EDGAR (opens in a new tab)